Extended interval dosing strategies in multiple sclerosis: insights from natalizumab and ocrelizumab trials. Zid Y, Robertson NP. J Neurol 2024 Mar 4. doi: 10.1007/s00415-024-12273.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Zid Y, Robertson NP. Extended interval dosing strategies in multiple sclerosis: insights from natalizumab and ocrelizumab trials. J Neurol 2024 Mar 4. doi: 10.1007/s00415-024-12273.
PMID: 38436677